Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.52 |
| ▸ | BTK | Q06187 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | TTK | P33981 | 6/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCND2 | P30279 | 1/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383660 | 1.00 | JAK3 (0.52) | JAK3BTKEGFRTTKALK | |
| SCHEMBL27912557 | 0.90 | JAK3 (0.50) | JAK3BTKEGFRTTKJAK1 | |
| SCHEMBL4382944 | 0.87 | PAK4 (0.59) | JAK3BTKEGFRTTKSYK | |
| SCHEMBL4382956 | 0.87 | PAK4 (0.59) | JAK3BTKEGFRTTKSYK | |
| SCHEMBL1019450 | 0.87 | JAK3 (0.55) | JAK3BTKEGFRTTKALK | |
| SCHEMBL1018408 | 0.86 | SYK (0.51) | JAK3BTKEGFRTTKSYK | |
| SCHEMBL1017585 | 0.86 | JAK3 (0.54) | JAK3BTKEGFRTTKALK | |
| SCHEMBL1018567 | 0.86 | PTK2 (0.50) | JAK3BTKEGFRTTKJAK1 | |
| SCHEMBL1074127 | 0.86 | PTK2 (0.50) | JAK3BTKEGFRTTKJAK1 | |
| SCHEMBL1019395 | 0.86 | EGFR (0.50) | JAK3BTKEGFRTTKALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | claimed |
| EP-2271631-B1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | JAK3 6/4885BTK 2/4885EGFR 805/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | JAK3 6/4885BTK 2/4885EGFR 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.